TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03736577

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug reviews with NorGeP-NH
Description: Physicians in the intervention group will attend a 1-2 hours lecture about psychopharmacology and drug review. They will learn how to do drug reviews with the Norwegian general practice criteria - Nursing homes (NorGeP-NH). The nursing home physicians will do the drug review on the participants' drug charts
Study: NCT03245658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC and CBD Mixture
Description: Individually titrated doses on daily basis
Study: NCT01717313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Description: Omarigliptin 25 mg capsule administered orally once a week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Omarigliptin
Description: Placebo to omarigliptin capsule administered orally once a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: If necessary, participants may have glycemic rescue therapy initiated with open-label metformin during Phase A of the study. Participants in the placebo treatment group who were not rescued with open-label metformin during Phase A will receive blinded metformin (starting at 500 mg orally twice daily with up-titration to 1000 mg orally twice daily) in Phase B. Participants in the omarigliptin treatment group who were rescued with open-label metformin in Phase A will continue open-label metformin during Phase B of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: If necessary, participants may have glycemic rescue therapy initiated with open-label metformin during Phase A of the study. Participants in the placebo treatment group who were not rescued with open-label metformin during Phase A will receive blinded metformin (starting at 500 mg orally twice daily with up-titration to 1000 mg orally twice daily) in Phase B. Participants in the omarigliptin treatment group who were rescued with open-label metformin in Phase A will continue open-label metformin during Phase B of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to metformin
Description: During Phase B of the study, participants in the omarigliptin treatment group who did not initiate glycemic rescue therapy during Phase A will receive placebo to metformin for 30 weeks (Phase B of the study).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: If necessary during Phase B of the study, participants will initiate open-label glimepiride as glycemic rescue therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glimepiride
Description: If necessary during Phase B of the study, participants will initiate open-label glimepiride as glycemic rescue therapy
Study: NCT04352062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Pantoprazole 40mg
Description: pantoprazole 2 x 40mg

Intervention type: DRUG
Group type: OTHER
Intervention: Amoxicillin
Description: Amoxicillin 2 x 1000mg

Intervention type: DRUG
Group type: OTHER
Intervention: Levofloxacin 500mg
Description: Levofloxacin 2 x 500mg
Study: NCT01090245

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management: voucher/monetary incentives for treatment attendance
Description: Contingency management: Escalation with reset for non-attendance. Daily. Up to $841.50 in incentives for treatment attendance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information
Description: Attendance Information Group will receive an individual information session along with a pamphlet describing the benefits of remaining in treatment after release from prison and on the benefits of HIV prevention and testing.
Study: NCT00075608

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: 16mcg/kg IV daily beginning three days prior to stem cell collection through last day of stem cell collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 140-200 mcg/kg IV over two days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous stem cell transplantation
Description: infusion of previously collected stem cells on Day 0

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stem cell infusion
Description: infusion of previously collected stem cells on Day 0
Study: NCT03615326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 800 mg/m\^2/day continuous on Days 1-5 of each 3-week cycle (120 hours or per local standard), administered as part of FP chemotherapy regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 800 mg/m\^2/day continuous on Days 1-5 of each 3-week cycle (120 hours or per local standard), administered as part of FP chemotherapy regimen.
Study: NCT01446445

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganciclovir/ Valganciclovir according to SPC
Description: Doses according to Summaries of Product Characteristics (SPC)
Study: NCT03615326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m\^2 on Day 1 of each 3-week cycle over 2 hours as an IV infusion, administered as part of CAPOX chemotherapy regimen and as part of SOX chemotherapy regimen.
Study: NCT01446445

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganciclovir/ Valganciclovir according to SPC
Description: Doses according to Summaries of Product Characteristics (SPC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir/ Valganciclovir according to PK model
Description: Doses according to population pharmacokinetic model

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir/ Valganciclovir according to PK model
Description: Doses according to population pharmacokinetic model
Study: NCT03615326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 130 mg/m\^2 on Day 1 of each 3-week cycle over 2 hours as an IV infusion, administered as part of CAPOX chemotherapy regimen and as part of SOX chemotherapy regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m\^2 as oral capsules BID on Days 1-14 of each 3-week cycle, administered as part of CAPOX chemotherapy regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000 mg/m\^2 as oral capsules BID on Days 1-14 of each 3-week cycle, administered as part of CAPOX chemotherapy regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Combination product of tegafur, CDHP, and Oxo. Oral capsules BID on Days 1-14 of each 3-week cycle based on body surface area (BSA): \<1.25 m\^2 BSA =40 mg, 1.25 to \<1.5 m\^2 BSA=50 mg, ≥1.5 m\^2 BSA=60 mg. Administered as part of SOX chemotherapy regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: Combination product of tegafur, CDHP, and Oxo. Oral capsules BID on Days 1-14 of each 3-week cycle based on body surface area (BSA): \<1.25 m\^2 BSA =40 mg, 1.25 to \<1.5 m\^2 BSA=50 mg, ≥1.5 m\^2 BSA=60 mg. Administered as part of SOX chemotherapy regimen.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8 mg/kg loading dose and then 6 mg/kg maintenance dose administered IV on day 1 of each 3-week cycle.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 8 mg/kg loading dose and then 6 mg/kg maintenance dose administered IV on day 1 of each 3-week cycle.
Study: NCT03438032

Intervention type: DIAGNOSTIC_TEST
Intervention: Bronchoscopy with lavage
Description: During an elective bronchoscopy procedure, the bronchoscope will be wedged into an affected lung segment guided by CT scanning. When involved an anterior segment will be used to maximize return. After wedging the bronchoscope, 120ml of sterile 0.09% normal saline will be instilled. Up to 40-60 mL of BAL fluid will be obtained for analysis during each sampling.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bronchoscopy with lavage
Description: During an elective bronchoscopy procedure, the bronchoscope will be wedged into an affected lung segment guided by CT scanning. When involved an anterior segment will be used to maximize return. After wedging the bronchoscope, 120ml of sterile 0.09% normal saline will be instilled. Up to 40-60 mL of BAL fluid will be obtained for analysis during each sampling.
Study: NCT00492401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01613820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: ketamine IV 0.25mg/kg infusions twice a week for 3 weeks as augmentation of ongoing antidepressant regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: ketamine IV 0.25mg/kg infusions twice a week for 3 weeks as augmentation of ongoing antidepressant regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: Scopolamine 2ug/kg over 15 minutes twice a week for 3 weeks as augmentation of ongoing antidepressant regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: Scopolamine 2ug/kg over 15 minutes twice a week for 3 weeks as augmentation of ongoing antidepressant regimen
Study: NCT03988374

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dentifrices
Description: Dentifrice on plaque, gingivitis, and bleeding.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dentifrices
Description: Dentifrice on plaque, gingivitis, and bleeding.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dentifrices
Description: Dentifrice on plaque, gingivitis, and bleeding.
Study: NCT00956540

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deflating tracheal cuff
Description: Deflating tracheal cuff during ventilatory disconnections along the weaning phase in patients tracheostomized for prolonged weaning or ventilatory support.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deflating tracheal cuff 2
Description: Deflating tracheal cuff during ventilatory disconnections along the weaning phase in patients tracheostomized for low level of consciousness or inability to adequate manage the airway.
Study: NCT00447330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)
Description: Capecitabine will be administered orally at a twice daily dose of 850 mg/m2 (equivalent to a total daily dose of 1700 mg/m2) given days 1-14 of the three week cycle.~Oxaliplatin will be administered at the dose of 130 mg/m2 given as a 2-hour intravenous infusion on day 1 of a three week cycle.~Bevacizumab will be administered at a dose of 15 mg/kg given as a 30-90 minute intravenous infusion on day 1 of a three week cycle following the administration of oxaliplatin.
Study: NCT03848091

Intervention type: OTHER
Intervention: Antibiotic pretreatment
Description: a strategy with antibiotic pretreatment before one-step exchange arthroplasty in patients who bacteria responsible for the infection has been indentified (puncture, blood cultures,...)
Study: NCT00671593

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: House Dust Mite
Description: Dermatophagoides pteronyssinus: nebulized inhaled dosing is every 10 minutes per protocol limits at the following Allergen Concentration , (5 breaths of duration 0.8 seconds using a dosimeter) 0.0 AU, 0.3 AU/ml,~1 AU/ml, 3 AU/ml, 10 AU/ml, 30 AU/ml, 100 AU/ml, 300 AU/ml, 1000 AU/ml, 3000 AU/ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diluent
Description: Greer lab allergen extract diluent (0.5% sodium chloride, 0.25% sodium bicarbonate, 50% glycerin (v/v), and 0.4% phenol)nebulized inhaled dosing is every 10 minutes per protocol limits at the following Diluent Concentration, (5 breaths of duration 0.8 seconds using a dosimeter)
Study: NCT02786043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propionyl-L-Carnitine Hydrochloride
Description: 1g twice a day on first 4 days and 1g/ day on day 5 during Phase III
Study: NCT03681821

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transtheoretical Model (TTM)-based Intervention
Description: Patients in the intervention group had access to conventional care, in addition to receiving the follow-up TTM-based intervention sessions. The intervention was provided by trained nurses, including one researcher and one ET nurse. Sessions were held in the meeting room in the unit four times: at baseline (T0), 2 days before discharge (T1), and at 1-month (T2) and 3-months (T3) after discharge, according to the assessment of their current stage of change delivered by filling the Stages of Change Subscale. Each face-to-face group contact lasted about 1 hour, depending on the complexity of the patients' problems.
Study: NCT02966483

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TaTME
Description: Transanal Total Mesorectal Excision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LpTME
Description: Conventional Laparoscopic Total Mesorectal Excision
Study: NCT03930186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Therapy
Description: Participants continued to use their existing topical treatment for psoriasis for the first 16 weeks. After 16 weeks, participants could decrease the use of topical therapy at their discretion under the direction of their physician.
Study: NCT01365520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa
Description: A single dose will be administered i.v. (into the vein). Subjects will be randomised to one of two lots of NNC 0155-0000-0004.
Study: NCT01330121

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist Counseling
Description: Pharmacist Counseling includes but is not limited to:~Reviewing and explaining their medications (dosing, side effects, route) Reviewing symptoms and complications of hyper and hypoglycemia Defining glycemic \& non-glycemic goal levels Explaining the importance of compliance with medications \& appointments Educating on the basics of nutrition and physical activity
Study: NCT00492401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high performance liquid chromatography
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RNA analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA methylation analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: matrix-assisted laser desorption/ionization time of flight mass spectrometry
Description: Correlative studies
Study: NCT00615706

Intervention type: OTHER
Intervention: No intervention
Description: no intervention

Intervention type: OTHER
Intervention: No intervention
Description: no intervention
Study: NCT00328263

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus CL1285 and Lactobacillus casei
Description: One bottle daily 2 hours before or after antibiotic administration and for 5 days following the termination of antibiotic regimen.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: One bottle daily 2 hours before or after antibiotic administration and for 5 days following the termination of antibiotic regimen.
Study: NCT03634215

Intervention type: DIAGNOSTIC_TEST
Intervention: fibrinogen plasma concentration, coagulation factor XIII activity
Description: blood sampling for a routine coagulation test
Study: NCT01810991

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nd:YAG Laser
Description: Nd:YAG 1440nm Laser
Study: NCT05028023

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Apneic oxygenation - supplemental high flow oxygen administration by an apneic way
Description: In pediatric patients undergoing tracheal balloon dilatation, oxygenation maintenance is essential, while induction in anesthesia, cessation of spontaneous ventilation by neuromuscular relaxant and pediatric i-gel placement are necessary for access to trachea. After i-Gel placement controlled ventilation with 100% oxygen is initiated. Pediatric bronchoscope and balloon dilatation catheter are advanced into trachea to the stenotic area. Overall dilatation duration is 2,5-3minutes, while the balloon is inflated for 60sec. Every dilatation cession consists of three dilatations. First dilatation is performed without oxygen enrichment. During second and third dilatation, a nelaton catheter, connected with high oxygen flow, is advanced into i-Gel canal, together with bronchoscope and balloon catheter. Effects of no oxygenation and apneic oxygenation in regional cerebral oxygen saturation rSO2, pulse oximetry SpO2, arterial blood gases and haemodynamics are recorded and compared.
Study: NCT02421120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane/Tazobactam
Description: 1 hour intravenous infusion
Study: NCT03424330

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReX-C intervention
Description: Patients receive medication by the ReX-C device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReX-C intervention
Description: Patients receive medication by the ReX-C device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Patients receive medication as usual

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Patients receive medication as usual
Study: NCT00882713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: Subcutaneous injection every 4 weeks (starting dose of 120, 200 or 360 micrograms, based on previous ESA therapy)
Study: NCT02852694

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Subcutaneous methotrexate once weekly 15mg/m2 body surface area (19, 30), with a maximal dose of 25mg/week. Odansetron (Zofran) premedication (4-8mg 1Hour prior to injection) is recommended, folate acid substitution (15mg po, 3 days after Methotrexate injection, for children \<20kg: 1x 5mg) is recommended.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Subcutaneous methotrexate once weekly 15mg/m2 body surface area (19, 30), with a maximal dose of 25mg/week. Odansetron (Zofran) premedication (4-8mg 1Hour prior to injection) is recommended, folate acid substitution (15mg po, 3 days after Methotrexate injection, for children \<20kg: 1x 5mg) is recommended.

Intervention type: DRUG
Group type: OTHER
Intervention: Adalimumab
Description: Subcutaneous Adalimumab started at a dose of 160mg followed by 80mg 2 weeks later and then 40mg every 2 weeks in patients over 40kg. In patients \< 40kg sc doses of Adalimumab are as follows: induction 160mg/1,73m2 BSA (max 160mg), followed by 80mg/1,73m2 Body surface area (max 80mg) 2 weeks later and maintenance of 40mg/1,73m2 Body surface area (max 40mg) every 2 weeks, all doses rounded up to the nearest 5 multiplications.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Subcutaneous Adalimumab started at a dose of 160mg followed by 80mg 2 weeks later and then 40mg every 2 weeks in patients over 40kg. In patients \< 40kg sc doses of Adalimumab are as follows: induction 160mg/1,73m2 BSA (max 160mg), followed by 80mg/1,73m2 Body surface area (max 80mg) 2 weeks later and maintenance of 40mg/1,73m2 Body surface area (max 40mg) every 2 weeks, all doses rounded up to the nearest 5 multiplications.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine / 6 Mercaptopurine
Description: Oral Azathioprine /6mercaptopurine at a dose of 2.5 mg/kg once daily rounded to the nearest multiplication of 12.5mg or oral 6mercaptopurine at a dose of 1.5mg/kg once daily rounded to the nearest multiplication of 12.5mg.
Study: NCT03159754

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Appendectomy
Description: Removal of the appendix within 24 hours of admission

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interval Appendectomy
Description: Removal of the appendix after initial antibiotic treatment and at least 6 weeks of recovery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: Zosyn will be administered unless the patient has a penicillin allergy, in which case patients will receive both ciprofloxacin and metronidazole.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: Zosyn will be administered unless the patient has a penicillin allergy, in which case patients will receive both ciprofloxacin and metronidazole.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: Zosyn will be administered unless the patient has a penicillin allergy, in which case patients will receive both ciprofloxacin and metronidazole.
Study: NCT00987051

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Detection of sentinel node
Description: Coelioscopy or laparotomy (based on the tumor size) after a colorimetric tracer injection
Study: NCT01623778

Intervention type: DRUG
Intervention: Interferon Alfa-2a add on ADV
Description: Interferon add on ADV for 48 weeks

Intervention type: DRUG
Intervention: Interferon Alfa-2a add on ADV
Description: Interferon add on ADV for 48 weeks
Study: NCT00748566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone HCL (oral)
Description: Ziprasidone Hydrochloride 20 to 80 mg administered orally twice a day (40 to 160 mg total daily dose) for up to 1 year.
Study: NCT01466894

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMM 124-E
Description: Tablets orally twice a day for 24 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMM 124-E
Description: Tablets orally twice a day for 24 weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets orally twice daily for 24 weeks
Study: NCT00354159

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Implantable Hemodynamic Monitor (Chronicle® IHM), and IHM in combination with single chamber ICD (Chronicle ICD)
Description: Surgical implantation of hemodynamic device (IHM), or IHM/ICD, and intracardiac leads.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Hemodynamic Monitor (Chronicle® IHM), and IHM in combination with single chamber ICD (Chronicle ICD)
Description: Surgical implantation of hemodynamic device (IHM), or IHM/ICD, and intracardiac leads.